NCT06046443Phase 2Completed

A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity

Study sponsor: Rhythm Pharmaceuticals, Inc. · RYTM

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-02-09Actual
Enrollment · participants28Actual
Source updated2026-10-30Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Mean percentage change in BMI Time frame: From Baseline to Week 14. After: Measure: Treatment Phase: Mean Percentage Change From Baseline to Week 14 in Body Mass Index (BMI) Description: BMI was calculated as weight (kilograms \[kg\])/height (squared meters \[m\^2\]). Least square mean (LSM) and standard error (SE) were calculated using analysis of covariance (ANCOVA) model with treatment group, randomization stratification factor (≥18 years old vs \<18 years old) as factors and baseline BMI as a covariate. Time frame: Baseline, Week 14.

Check registry source

· 4 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: 31 Jan 2026. After: 9 Feb 2026.

Recruitment status changed

Before: Active not recruiting. After: Completed.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview